摘要
目的分析阿托伐他汀与瑞舒伐他汀对缺血性脑卒中患者的调脂效果。方法80例缺血性脑卒中患者,随机分为参考组和研究组,每组40例。参考组患者采用阿托伐他汀治疗,研究组患者采用瑞舒伐他汀治疗。比较两组患者用药前后血脂水平以及颈动脉(左颈内动脉、右颈内动脉、左颈总动脉、右颈总动脉)内膜中层厚度(IMT)、用药后不良反应发生情况。结果用药前后,两组患者左颈内动脉、右颈内动脉、左颈总动脉、右颈总动脉IMT比较差异均无统计学意义(P>0.05);用药前,两组患者低密度脂蛋白胆固醇(LDL-C)水平比较差异无统计学意义(P>0.05);用药后,研究组患者LDL-C水平(2.12±0.63)mmol/L低于参考组的(2.43±0.54)mmol/L,差异具有统计学意义(P<0.05)。研究组患者用药后不良反应发生率为5.00%,明显低于参考组的25.00%,差异具有统计学意义(P<0.05)。结论缺血性脑卒中患者采用瑞舒伐他汀的调脂效果显著,值得在临床中广泛应用。
Objective To analyze the effect of atorvastatin and rosuvastatin on lipid regulation in patients with ischemic stroke.Methods A total of 80 patients with ischemic stroke were randomly divided into reference group and research group,with 40 cases in each group.The reference group was treated with atorvastatin,and the research group was treated with rosuvastatin.The blood lipid levels,intima-media thickness(IMT)of carotid artery(left internal carotid artery,right internal carotid artery,left common carotid artery,right common carotid artery)before and after medication and occurrence of adverse reactions were compared between the two groups.Results After medication,there was no statistically significant difference in IMT of left internal carotid artery,right internal carotid artery,left common carotid artery,right common carotid artery between the two groups(P>0.05).Before medication,there was no statistically significant difference in low-density lipoprotein cholesterol(LDL-C)between the two groups(P>0.05).After medication,LDL-C(2.12±0.63)mmol/L of the research group was lower than(2.43±0.54)mmol/L of the reference group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions after medication of the research group was 5.00%,which was obviously lower than 25.00%of the reference group,and the difference was statistically significant(P<0.05).Conclusion Rosuvastatin has a significant lipid-lowering effect in patients with ischemic stroke,which is worthy of being widely used in clinical practice.
作者
王红洁
WANG Hongjie(Benxi Ninth People’s Hospital,Benxi 117000,China)
出处
《中国现代药物应用》
2020年第22期82-84,共3页
Chinese Journal of Modern Drug Application